Townsquare Capital LLC Sells 8,154 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Townsquare Capital LLC reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 76.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,546 shares of the medical research company’s stock after selling 8,154 shares during the quarter. Townsquare Capital LLC’s holdings in Charles River Laboratories International were worth $470,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth about $601,000. Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the 3rd quarter valued at approximately $59,000. Tidal Investments LLC boosted its position in Charles River Laboratories International by 37.8% during the 3rd quarter. Tidal Investments LLC now owns 8,452 shares of the medical research company’s stock worth $1,665,000 after acquiring an additional 2,319 shares during the last quarter. Lord Abbett & CO. LLC grew its stake in shares of Charles River Laboratories International by 5.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company’s stock worth $21,413,000 after acquiring an additional 5,959 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Charles River Laboratories International by 3.6% in the third quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company’s stock valued at $11,917,000 after purchasing an additional 2,126 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent research reports. UBS Group restated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Barclays reduced their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their target price for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. JPMorgan Chase & Co. decreased their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $182.00.

Charles River Laboratories International Stock Up 1.6 %

CRL opened at $105.89 on Monday. The stock has a fifty day moving average of $151.07 and a 200-day moving average of $173.76. The company has a market capitalization of $5.20 billion, a P/E ratio of 705.91, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).